Abstract
D-Amino acid oxidase (DAAO) catalyzes the oxidative metabolism of D-amino acids including D-serine, a full agonist at the allosteric glycine binding site of the NMDA receptor. D-serine was reported to improve negative and cognitive symptoms of schizophrenia, symptoms poorly addressed by the standard D2 antagonist therapies. Therefore, inhibition of DAAO has gained substantial interest as an effective way to increase D-serine levels in the brain. During the last several years, a growing number of structurally diverse DAAO inhibitors have been identified with significantly higher inhibitory potency compared to the conventional DAAO inhibitors. Some of these new generation of DAAO inhibitors are being evaluated for their ability to enhance D-serine levels in rodents and efficacy in animal models of schizophrenia. This article highlights the progress that has been made toward the discovery of DAAO inhibitors and recent efforts to exploit their therapeutic utility in schizophrenia.
Keywords: D-amino acid oxidase, D-serine, NMDA receptors, schizophrenia
Current Pharmaceutical Design
Title: Recent Advances in the Discovery of D-Amino Acid Oxidase Inhibitors and Their Therapeutic Utility in Schizophrenia
Volume: 17 Issue: 2
Author(s): Dana V. Ferraris and Takashi Tsukamoto
Affiliation:
Keywords: D-amino acid oxidase, D-serine, NMDA receptors, schizophrenia
Abstract: D-Amino acid oxidase (DAAO) catalyzes the oxidative metabolism of D-amino acids including D-serine, a full agonist at the allosteric glycine binding site of the NMDA receptor. D-serine was reported to improve negative and cognitive symptoms of schizophrenia, symptoms poorly addressed by the standard D2 antagonist therapies. Therefore, inhibition of DAAO has gained substantial interest as an effective way to increase D-serine levels in the brain. During the last several years, a growing number of structurally diverse DAAO inhibitors have been identified with significantly higher inhibitory potency compared to the conventional DAAO inhibitors. Some of these new generation of DAAO inhibitors are being evaluated for their ability to enhance D-serine levels in rodents and efficacy in animal models of schizophrenia. This article highlights the progress that has been made toward the discovery of DAAO inhibitors and recent efforts to exploit their therapeutic utility in schizophrenia.
Export Options
About this article
Cite this article as:
V. Ferraris Dana and Tsukamoto Takashi, Recent Advances in the Discovery of D-Amino Acid Oxidase Inhibitors and Their Therapeutic Utility in Schizophrenia, Current Pharmaceutical Design 2011; 17 (2) . https://dx.doi.org/10.2174/138161211795049633
DOI https://dx.doi.org/10.2174/138161211795049633 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gut-Brain Axis in Gastric Mucosal Damage and Protection
Current Neuropharmacology The Perfect Storm: The High Prevalence Low Severity Outcomes of the Preterm Survivors
Current Pediatric Reviews Somatic Genome Variations in Health and Disease
Current Genomics Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets mGluRI Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways
Current Neurovascular Research Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease
Current Pharmaceutical Design Prion Protein Misfolding and Brain Degeneration
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Tyrosyl-DNA Phosphodiesterase 1 Targeting for Modulation of Camptothecin-Based Treatment
Current Medicinal Chemistry Neurotoxins: Free Radical Mechanisms and Melatonin Protection
Current Neuropharmacology Ras Family Small GTPase-Mediated Neuroprotective Signaling in Stroke
Central Nervous System Agents in Medicinal Chemistry Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Treatment of Viral Encephalitis
Central Nervous System Agents in Medicinal Chemistry The Influence of Thyroid Hormone on Ca<sup>2+</sup> Signaling Pathways During Embryonal Development
Current Topics in Medicinal Chemistry Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery The Implications of Iodine and its Supplementation During Pregnancy in Fetal Brain Development
Current Clinical Pharmacology γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Noninvasive Cerebellar Stimulation as a Complement Tool to Pharmacotherapy
Current Neuropharmacology